WO2016049746A1 - Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid - Google Patents
Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid Download PDFInfo
- Publication number
- WO2016049746A1 WO2016049746A1 PCT/CA2015/000521 CA2015000521W WO2016049746A1 WO 2016049746 A1 WO2016049746 A1 WO 2016049746A1 CA 2015000521 W CA2015000521 W CA 2015000521W WO 2016049746 A1 WO2016049746 A1 WO 2016049746A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- component
- inflammatory
- chronic
- tube
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- a method of treating a mammal for damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders comprising the following steps: collecting blood from the mammal;
- Figure 17 is a graph showing a comparison of the level of PDGF in the human serum samples before (baseline level) and after incubation in 37°C for 24h, activated PRP and in the final composition.
- Figure 18c is a plot showing point values according to the WOMAC index for average levels of daily activity capabilities among the seventeen patients tested. Values are provided for a baseline and 1 month post injections for CA- and CA+ groups.
- Such a composition typically includes the following therapeutically active proteins: IL-lra 6 , IL- 4 7 , IL-10 8 ' 9 , IL-13 10 , PDGF 11 , TGF- ⁇ 10 ' 11 and VEGF 12 ' 13 14 ' 16 .
- TIMPs tissue inhibitors of metalloproteinases
- the site of venipuncture and the surface of the collection tubes may be cleaned with a 2 percent tincture of iodine solution. Before any cleansing of the site is begun, the patient may be asked about any allergy to iodine.
- the tube covers are cleaned with 70% alcohol solution also to avoid possible contamination before blood collection.
- the incubated blood is then subjected to centrifugation to separate the supernatant component from the cellular fraction.
- the centrifugation is carried out for about 10-20 minutes at about 4000-10000 rpm.
- Preferably the centrifugation is carried out for 10 minutes at 4000 rpm.
- the anti-inflammatory/anti-catabolic component of the autologous composition comprising IL-lra and TIMPs, was prepared by: collecting blood from the patient; delivering the blood to a tube; incubating the blood at a temperature of from about 37°C to about 39°C for about 24 hours; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component of the antiinflammatory component.
- Figure 9 is graph showing a comparison between the average concentration level of PGDF in the unprocessed human serum samples and an average level of PGDF in 24h incubated samples. Test data analysis showed a statistically significant increase of PGDF protein concentration in processed samples. PDGF concentration was evaluated using MAGPIX LuminexTM technology.
- Figure 7 is a plot showing point values according to the WOMAC index for average levels of pain, stiffness and daily activity capabilities among the eight patients. Values are provided for a baseline, after injections, two months and three months post injections.
- Figure 8 shows results in the form of a graph among the eight patients providing a breakdown of the average results after the first, second, third injections, two months and three months post the fourth injection.
- Serum Oh is the baseline measurement of the level of the analyte in the patients' blood measured immediately upon collection.
- Serum 24h + 0.5cc saline is the level of the analyte in the patients' blood mixed with saline solution after 24 hours of incubation.
- Serum 24h + 0.5 cc CA is the level of the analyte in the patients' blood mixed with 4% sodium citrate solution after 24 hours of incubation.
- PRP + Thrombin is the level of the analyte in the PRP component combined with thrombin as a clotting agent. This measurement shows a baseline level of analyte in the PRP component.
- Example 2 The methods of Example 2 are performed with and without the addition of sodium citrate in preparing the anti- inflammatory/anti-catabolic component on subjects suffering from chronic inflammatory skin diseases such as atopic dermatitis and chronic wounds.
- chronic inflammatory skin diseases such as atopic dermatitis and chronic wounds.
- the chronic inflammatory skin diseases reduce in severity.
- Example 8 Horses, Dogs and Camels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LTEPPCT/CA2015/000521T LT3200817T (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous blood |
ES15847588T ES2912773T3 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing improved anti-inflammatory/anti-catabolic and regenerative agents from autologous blood |
CA2962289A CA2962289C (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
CN201580053264.6A CN107073083B (en) | 2014-09-30 | 2015-09-30 | Methods and compositions for producing enhanced anti-inflammatory/anti-catabolic agents and regenerative agents from autologous physiological fluids |
AU2015327723A AU2015327723B2 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
GB1706803.2A GB2546224B (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
BR112017006410A BR112017006410A2 (en) | 2014-09-30 | 2015-09-30 | method and composition for the production of anti-inflammatory / anticatabolic agents and autologous physiological fluid regenerating agents |
KR1020177011345A KR102455394B1 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
JP2017518238A JP6646660B2 (en) | 2014-09-30 | 2015-09-30 | Methods and compositions for making enhanced anti-inflammatory / anti-catabolic and regenerative substances from autologous physiological fluids |
RU2017114523A RU2708242C2 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing intensified anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
US15/515,996 US10532072B2 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
EP15847588.9A EP3200817B1 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous blood |
MX2017004131A MX2017004131A (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid. |
IL251082A IL251082B (en) | 2014-09-30 | 2017-03-09 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
US16/741,627 US20200163991A1 (en) | 2014-09-30 | 2020-01-13 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2866480 | 2014-09-30 | ||
CA2866480A CA2866480A1 (en) | 2014-09-30 | 2014-09-30 | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
CA2891445 | 2015-05-14 | ||
CA2891445A CA2891445A1 (en) | 2014-09-30 | 2015-05-14 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
CA2900537A CA2900537A1 (en) | 2014-09-30 | 2015-08-13 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
CA2900537 | 2015-08-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/515,996 A-371-Of-International US10532072B2 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
US16/741,627 Continuation US20200163991A1 (en) | 2014-09-30 | 2020-01-13 | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016049746A1 true WO2016049746A1 (en) | 2016-04-07 |
Family
ID=55590205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2015/000521 WO2016049746A1 (en) | 2014-09-30 | 2015-09-30 | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
Country Status (16)
Country | Link |
---|---|
US (2) | US10532072B2 (en) |
EP (1) | EP3200817B1 (en) |
JP (1) | JP6646660B2 (en) |
KR (1) | KR102455394B1 (en) |
CN (1) | CN107073083B (en) |
AU (1) | AU2015327723B2 (en) |
BR (1) | BR112017006410A2 (en) |
CA (4) | CA2866480A1 (en) |
CL (1) | CL2017000670A1 (en) |
ES (1) | ES2912773T3 (en) |
GB (1) | GB2546224B (en) |
IL (1) | IL251082B (en) |
LT (1) | LT3200817T (en) |
MX (1) | MX2017004131A (en) |
RU (1) | RU2708242C2 (en) |
WO (1) | WO2016049746A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018102909A1 (en) * | 2016-12-06 | 2018-06-14 | Antnor Limited | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma |
US10532072B2 (en) | 2014-09-30 | 2020-01-14 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
WO2020243807A1 (en) * | 2019-06-05 | 2020-12-10 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
WO2021184116A1 (en) * | 2020-03-17 | 2021-09-23 | Antnor Limited | Method for producing enhanced anti-inflammatory/ anti-catabolic agents from autologous physiological fluid |
WO2022155729A1 (en) * | 2021-01-20 | 2022-07-28 | Antnor Limited | Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613424A1 (en) * | 2018-08-23 | 2020-02-26 | Orthogen AG | Novel methods for the production of pharmaceutical agents |
RU2747589C1 (en) * | 2019-12-09 | 2021-05-11 | Руслан Яверович Атлуханов | Method for treating meniscus injury of knee joint |
JP7025070B1 (en) * | 2021-05-14 | 2022-02-24 | セルソース株式会社 | Blood-derived growth factor-containing composition and its preparation method |
JP7175055B1 (en) * | 2021-05-14 | 2022-11-18 | セルソース株式会社 | Blood-derived growth factor-containing composition and method for preparing the same |
CN114146096B (en) * | 2021-11-25 | 2024-04-02 | 成都清科生物科技有限公司 | Preparation method and application of conditional serum rich in cytokines |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138910A1 (en) * | 1999-02-01 | 2003-07-24 | Julio Reinecke | Method for producing interleukin 1 receptor antagonists, a therapeutic activity protein, from body fluids |
US20100125236A1 (en) * | 2008-11-17 | 2010-05-20 | Christopher Bare | Cytokine concentration system |
KR20130027083A (en) | 2010-12-09 | 2013-03-15 | 이선민 | Method for preparing autologous thrombin activated autologous plasma for regeneration of epithelial tissues or subcutaneous tissues and composition containing the autologous plasma |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69532236D1 (en) | 1994-12-16 | 2004-01-15 | Baxter Int | Anticoagulant compositions for platelets |
US20060177515A1 (en) | 2005-02-09 | 2006-08-10 | Reinhold Schmieding | Method of producing autogenous or allogenic blood serum and related logistics |
GB0700940D0 (en) | 2007-01-18 | 2007-02-28 | Univ Newcastle | Reverse shoulder prosthesis |
EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9763875B2 (en) | 2009-08-27 | 2017-09-19 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
EP2611456A2 (en) | 2010-09-03 | 2013-07-10 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
US10167310B2 (en) | 2012-01-31 | 2019-01-01 | Estar Technologies Ltd | System and method for producing interleukin receptor antagonist (IRA) |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
CA2866480A1 (en) | 2014-09-30 | 2016-03-30 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
-
2014
- 2014-09-30 CA CA2866480A patent/CA2866480A1/en not_active Abandoned
-
2015
- 2015-05-14 CA CA2891445A patent/CA2891445A1/en not_active Abandoned
- 2015-08-13 CA CA2900537A patent/CA2900537A1/en not_active Abandoned
- 2015-09-30 JP JP2017518238A patent/JP6646660B2/en active Active
- 2015-09-30 ES ES15847588T patent/ES2912773T3/en active Active
- 2015-09-30 LT LTEPPCT/CA2015/000521T patent/LT3200817T/en unknown
- 2015-09-30 WO PCT/CA2015/000521 patent/WO2016049746A1/en active Application Filing
- 2015-09-30 CA CA2962289A patent/CA2962289C/en active Active
- 2015-09-30 AU AU2015327723A patent/AU2015327723B2/en active Active
- 2015-09-30 CN CN201580053264.6A patent/CN107073083B/en active Active
- 2015-09-30 GB GB1706803.2A patent/GB2546224B/en active Active
- 2015-09-30 BR BR112017006410A patent/BR112017006410A2/en active Search and Examination
- 2015-09-30 EP EP15847588.9A patent/EP3200817B1/en active Active
- 2015-09-30 MX MX2017004131A patent/MX2017004131A/en unknown
- 2015-09-30 KR KR1020177011345A patent/KR102455394B1/en active IP Right Grant
- 2015-09-30 RU RU2017114523A patent/RU2708242C2/en active
- 2015-09-30 US US15/515,996 patent/US10532072B2/en active Active
-
2017
- 2017-03-09 IL IL251082A patent/IL251082B/en active IP Right Grant
- 2017-03-20 CL CL2017000670A patent/CL2017000670A1/en unknown
-
2020
- 2020-01-13 US US16/741,627 patent/US20200163991A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030138910A1 (en) * | 1999-02-01 | 2003-07-24 | Julio Reinecke | Method for producing interleukin 1 receptor antagonists, a therapeutic activity protein, from body fluids |
US20100125236A1 (en) * | 2008-11-17 | 2010-05-20 | Christopher Bare | Cytokine concentration system |
KR20130027083A (en) | 2010-12-09 | 2013-03-15 | 이선민 | Method for preparing autologous thrombin activated autologous plasma for regeneration of epithelial tissues or subcutaneous tissues and composition containing the autologous plasma |
Non-Patent Citations (26)
Title |
---|
ALVAREZ RH1KANTARJIAN HMCORTES JE: "Biology of platelet-derived growth factor and its involvement in disease", MAYO CLIN PROC, vol. 81, no. 9, September 2006 (2006-09-01), pages 1241 - 57 |
ANDIA, I. ET AL.: "Joint pathology and platelet-rich plasma therapies", EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 12, no. 1, 2012, pages 7 - 22, XP055424708, ISSN: 1471-2598 * |
BRANDTZAEG PIOSNES LOVSTEBO RJOO GBWESTVIK ABKIERULF P: "Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes", J EXP MED, vol. 184, no. 1, 1 July 1996 (1996-07-01), pages 51 - 60, XP008130884, DOI: 10.1084/jem.184.1.51 |
CLARKE CJ1HALES AHUNT AFOXWELL BM: "IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity", EUR J IMMUNOL, vol. 28, no. 5, May 1998 (1998-05-01), pages 1719 - 26 |
DE WAAL MALEFYT RFIGDOR CGHUIJBENS RMOHAN-PETERSON SBENNETT BCULPEPPER JDANG WZURAWSKI GDE VRIES JE: "Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10", J IMMUNOL, vol. 151, no. 11, 1 December 1993 (1993-12-01), pages 6370 - 81 |
DINARELLO CA: "Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist", INT REV IMMUNOL, vol. 16, no. 5-6, 1998, pages 457 - 99, XP001059110 |
EMING SAKRIEG TDAVIDSON JM: "Inflammation in wound repair: molecular and cellular mechanisms", J INVEST DERMATOL, vol. 127, 2007, pages 514, XP008159824, DOI: 10.1038/sj.jid.5700701 |
FERNANDES JCMARTEL-PELLETIER JPELLETIER JP: "The role of cytokines in osteoarthritis pathophysiology", BIORHEOLOGY, vol. 39, no. 1-2, 2002, pages 237 - 46 |
FREDBERG USTENGAARD-PEDERSEN K: "Chronic tendinopathy tissue pathology, pain mechanisms, and etiology with a special focus on inflammation", SCAND J MED SCI SPORTS, vol. 18, no. 1, February 2008 (2008-02-01), pages 3 - 15 |
FUFA DSHEALY BJACOBSON M ET AL.: "Activation of platelet-rich plasma using soluble Type I collagen", J ORAL MAXILLOFAC SURG, vol. 66, 2008, pages 684 - 90, XP025764340, DOI: 10.1016/j.joms.2007.06.635 |
GOSPODAROWICZ, D.ABRAHAM, J. A.SCHILLING, J: "Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells", PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 7311 - 7315 |
HIRATA HNAGAKURA TTSUJII MMORITA AFUJISAWA KUCHIDA A: "The relationship of VEGF and PGE2 expression to extracellular matrix remodelling of the tenosynovium in the carpal tunnel syndrome", J PATHOL, vol. 204, no. 5, December 2004 (2004-12-01), pages 605 - 12 |
LICHTENAUER, M. ET AL.: "Phosphate buffered saline containing calcium and magnesium elicits increased secretion of interleukin-1 receptor antagonist", LABORATORY MEDICINE, vol. 4 C, no. 5, 2009, pages 290 - 293, XP055424703, ISSN: 0007-5027 * |
LOELL ILUNDBERG IE: "Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?", J INTERN MED, vol. 269, no. 3, March 2011 (2011-03-01), pages 243 - 57, XP055080112, DOI: 10.1111/j.1365-2796.2010.02334.x |
MANNELLO F: "Serum or plasma samples? The ''Cinderella'' role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation", ARTERIOSCLER THROMB VASC BIOL, vol. 28, no. 4, April 2008 (2008-04-01), pages 611 - 4 |
MISHRA, A. ET AL.: "Treatment of chronic elbow tendinosis with buffered platelet-rich plasma", THE AMERICAN JOURNAL OF SPORTS MEDICINE, vol. 34, no. 11, pages 1774 - 1778, XP008100245, ISSN: 0363-5465 * |
MOSMANN TRCHERWINSKI HBOND MWGIEDLIN MACOFFMAN RL: "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins", J IMMUNOL, vol. 136, no. 7, 1 April 1986 (1986-04-01), pages 2348 - 57 |
PENG HUSAS AOLSHANSKI AHO AMGEARHART BCOOPER GMHUARD J: "VEGF improves, whereas sFltl inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis", J BONE MINER RES, vol. 20, no. 11, November 2005 (2005-11-01), pages 2017 - 27 |
POUTSIAKA DDCLARK BDVANNIER EDINARELLO CA: "Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated", BLOOD, vol. 78, no. 5, 1 September 1991 (1991-09-01), pages 1275 - 81 |
RITA EMIRZAMILIE M. FANG1 WILLIAM JTIMOTHY J. KOH: "Blocking Interleukin-1 β Induces a Healing-Associated Wound Macrophage Phenotype and Improves Healing in Type 2 Diabetes", DIABETES, vol. 62, no. 7, July 2013 (2013-07-01), pages 2579 - 2587, XP055652633, DOI: 10.2337/db12-1450 |
ROBERTS ABFLANDERS KCKONDAIAH PTHOMPSON NLVAN OBBERGHEN-SCHILLING EWAKEFIELD LROSSI PDE CROM-BRUGGHE BHEINE UI: "Sporn MB: Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis", REC PROG HORM RES, vol. 44, 1988, pages 157 - 197 |
ROBERTS ABHEINE UIFLANDERS KC: "Sporn MB: TGF-beta: Major role in regulation of extracellular matrix. Ann NY Acad Sci.", STRUCTURE, MOLECULAR BIOLOGY AND PATHOLOGY OF COLLAGEN, vol. 580, 1990, pages 225 - 232 |
SAMPSON, S. ET AL.: "Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis", AMERICAN JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, vol. 89, no. 12, 2010, pages 961 - 969, XP055424722, ISSN: 0894-9115 * |
SANCHEZ, M. ET AL.: "Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis in the hip", RHEUMATOLOGY, vol. 51, no. 1, 10 November 2011 (2011-11-10), pages 144 - 150, XP055424714, ISSN: 1462-0324 * |
See also references of EP3200817A4 |
WEHLING, P. ET AL.: "Autologous conditioned serum in the treatment of orthopedic diseases.", THE ORTHOKINE THERAPY. BIODRUGS., vol. 21, no. 5, 2007, pages 323 - 332, XP009501553, ISSN: 1173-8804 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10532072B2 (en) | 2014-09-30 | 2020-01-14 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid |
WO2018102909A1 (en) * | 2016-12-06 | 2018-06-14 | Antnor Limited | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma |
GB2574333A (en) * | 2016-12-06 | 2019-12-04 | Antnor Ltd | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma |
WO2020243807A1 (en) * | 2019-06-05 | 2020-12-10 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid |
WO2021184116A1 (en) * | 2020-03-17 | 2021-09-23 | Antnor Limited | Method for producing enhanced anti-inflammatory/ anti-catabolic agents from autologous physiological fluid |
WO2022155729A1 (en) * | 2021-01-20 | 2022-07-28 | Antnor Limited | Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines |
Also Published As
Publication number | Publication date |
---|---|
IL251082A0 (en) | 2017-04-30 |
CA2891445A1 (en) | 2016-03-30 |
CA2962289C (en) | 2021-01-19 |
US20200163991A1 (en) | 2020-05-28 |
JP6646660B2 (en) | 2020-02-14 |
KR20170063836A (en) | 2017-06-08 |
EP3200817A1 (en) | 2017-08-09 |
AU2015327723B2 (en) | 2020-10-22 |
CA2962289A1 (en) | 2016-04-07 |
US10532072B2 (en) | 2020-01-14 |
CA2900537A1 (en) | 2016-03-30 |
RU2708242C2 (en) | 2019-12-05 |
ES2912773T3 (en) | 2022-05-27 |
IL251082B (en) | 2020-03-31 |
CA2866480A1 (en) | 2016-03-30 |
LT3200817T (en) | 2022-08-10 |
CN107073083B (en) | 2021-07-06 |
BR112017006410A2 (en) | 2017-12-19 |
MX2017004131A (en) | 2017-06-19 |
GB201706803D0 (en) | 2017-06-14 |
RU2017114523A3 (en) | 2019-05-06 |
GB2546224B (en) | 2020-04-22 |
RU2017114523A (en) | 2018-11-07 |
JP2017533896A (en) | 2017-11-16 |
GB2546224A (en) | 2017-07-12 |
US20170296583A1 (en) | 2017-10-19 |
CN107073083A (en) | 2017-08-18 |
KR102455394B1 (en) | 2022-10-17 |
AU2015327723A1 (en) | 2017-04-13 |
EP3200817A4 (en) | 2018-06-20 |
EP3200817B1 (en) | 2022-03-02 |
CL2017000670A1 (en) | 2017-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200163991A1 (en) | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid | |
Nishio et al. | Platelet-rich plasma promotes recruitment of macrophages in the process of tendon healing | |
US7897180B2 (en) | Enamel matrix protein composition for treatment of systemic inflammatory response | |
US20190328792A1 (en) | Mesenchymal stem cell-derived extracellular vesicles and their medical use | |
Anitua et al. | Platelet Rich Plasma in Orthopaedics and Sports Medicine | |
US20190343878A1 (en) | Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma | |
WO2020243807A1 (en) | Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid | |
US20230146680A1 (en) | Method for producing enhanced anti-inflammatory / anti-catabolic agents from autologous physiological fluid | |
US20100297074A1 (en) | Wound healing compositions, systems, and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15847588 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 251082 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2962289 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/004131 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2017518238 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15515996 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017006410 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015327723 Country of ref document: AU Date of ref document: 20150930 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177011345 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015847588 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 201706803 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20150930 |
|
ENP | Entry into the national phase |
Ref document number: 2017114523 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017006410 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170328 |